Search Results
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
which is expected to be initiated in 2026.Phase 1/2 mUC Study – SURF301. Dabogratinib continues to be evaluated in Part B of SURF301 at potentially therapeutic once-daily doses in support of determining an optimal dose for mUC.
More news about: Tyra Biosciences
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
advanced or metastatic urothelial cancer (la/mUC) regardless of cisplatin eligibility in the United States, the European Union, Japan and a number of other countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1
More news about: Astellas Pharma Inc.
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
providing high-level evidence for HER2-ADC as a first-line treatment of HER2-expressing (IHC 1+/2+/3+) locally advanced/metastatic urothelial carcinoma (la/mUC). The results garnered high attention and sparked lively discussion among global scholars upon release. Comprehensive
More news about: RemeGen Co., Ltd
Oct 19, 2025, 03:00 ET Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Level 2 About AMT-253 AMT-253, a MUC18 ADC, is composed of a proprietary antibody with high MUC18 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1
More news about: Multitude Therapeutics, Inc.
Oct 19, 2025, 03:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公布其抗MUC18 ADC（AMT-253）用於晚期惡性黑色素瘤及其他實體瘤的初步積極數據
AMT-253 是一款潛在全球首創的靶向 MUC18 的抗體偶聯藥物 AMT-253 展現出良好可控的安全性，與其他 TOP1
More news about: 普眾發現
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
advanced or metastatic urothelial cancer (la/mUC) regardless of cisplatin eligibility in the United States, Japan, and a number of other countries around the world. In the European Union, the combination is approved for the treatment of adult patients with la/mUC who are eligible for platinum-containing
More news about: Astellas Pharma Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
an oral presentation followed by expert discussion and perspectives of initial results of a first-in human study: A tumor-associated Mucin 1 (TA-MUC1)–directed Antibody–drug Conjugate (ADC), in Patients (pts) with Advanced/Metastatic (adv/met) Solid Tumors.
More news about: Florida Cancer Specialists & Research Institute
Oct 09, 2025, 17:31 ET Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
is being investigated for the treatment of resistant disease. Additionally, immunotherapy-based approaches, including ubamatamab (REGN4018), a MUC16-targeted bispecific T-cell engager with or without cemiplimab, and the AKT inhibitor afuresertib (LAE002) in combination with paclitaxel, highlight
More news about: DelveInsight Business Research, LLP